Erica Conley
Family · Florence, ALNPI 1972919165
Payments from drug & device makers
Across 810 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Medtronic$2K
- Boehringer Ingelheim$978
- Abbott$811
- AstraZeneca$805
- plus $7K from 36 others
What the payments were for
- Food & beverage$15,811100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 129 | $2,281 |
| Novo Nordisk | 125 | $2,031 |
| Medtronic | 97 | $1,983 |
| Boehringer Ingelheim | 66 | $978 |
| Abbott | 23 | $811 |
| AstraZeneca | 30 | $805 |
| AbbVie | 49 | $796 |
| Sanofi-aventis U.S. LLC | 44 | $726 |
| Corcept Therapeutics | 29 | $628 |
| Xeris Pharmaceuticals, Inc. | 29 | $597 |
| Dexcom, Inc. | 25 | $544 |
| Tandem Diabetes Care, Inc. | 10 | $487 |
| Amgen | 24 | $441 |
| Bayer | 21 | $409 |
| IBSA Pharma Inc. | 17 | $337 |
| Amarin Pharma, Inc. | 13 | $258 |
| Sequel Med Tech, LLC | 7 | $223 |
| GSK | 4 | $180 |
| Insulet Corporation | 8 | $166 |
| Pfizer | 7 | $139 |
| Recordati_rare_diseases_inc. | 7 | $129 |
| Merck | 8 | $117 |
| Esperion Therapeutics, Inc. | 3 | $98 |
| Zealand Pharma US, Inc. | 5 | $94 |
| Ascensia Diabetes Care US Inc. | 4 | $89 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $50 |
| BD | 2 | $46 |
| Boston Scientific | 1 | $45 |
| Chiesi USA, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| GRT US Holding, Inc. | 2 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Soleno Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$626
- FreeStyle Libre 2$419
- FARXIGA$368
- t:slim X2 Insulin Pump with Control-IQ$251
- FreeStyle Libre$153
- TWIIST$133
- AREXVY$125
- Korlym$110
How this compares
$15,864 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 537 | $663,381 |
| OzempicSemaglutide | 309 | $466,904 |
| JardianceEmpagliflozin | 227 | $230,423 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 120 | $132,838 |
| TrulicityDulaglutide | 92 | $132,707 |
| FarxigaDapagliflozin Propanediol | 117 | $111,938 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $105,125 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $88,589 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $82,788 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 73 | $74,108 |
| Xigduo XrDapaglifloz Propaned/Metformin | 62 | $64,050 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 61 | $58,189 |
| CreonLipase/Protease/Amylase | 11 | $52,973 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $52,010 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $46,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $2,281 | $813,995693 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Rybelsus | $2,031 | $527,884378 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi | $978 | $347,138353 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $726 | $132,838120 claims |
| AstraZenecaFarxiga | $805 | $111,938117 claims |
| AbbVieCreon, Synthroid | $796 | $66,219154 claims |
| MerckJanumet Xr | $117 | $6,12412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $2,520255 claims |
| IBSA Pharma Inc.Tirosint-Sol | $337 | $2,31817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Florence
- Crystal KeetonFlorence$14K
- Angela GannFlorence$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.